• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Cost Analysis of DPP4 and SGLT2 Inhibitors - “Dilemma of the Prescribing Physician - Which Brand to Choose?”
  • VIEWS 144
  • PDF 84

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v23.2.15

Year: 2024, Volume: 23, Issue: 2, Pages: 77-82

Original Article

Cost Analysis of DPP4 and SGLT2 Inhibitors - “Dilemma of the Prescribing Physician - Which Brand to Choose?”

Hiteswar Saikia1,∗, Prabhat Ranjan Baruah2, Anju L Saikia1

1Assistant Professor, Department of Pharmacology, Assam Medical College and Hospital, Dibrugarh, Assam, India
2Associate Professor, Department of Physiology, Assam Medical College and Hospital, Dibrugarh, Assam, India

*Corresponding Author
Email: [email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Diabetes mellitus (DM) is a complex and heterogeneous group of chronic metabolic diseases causing dreaded complications increasing human sufferings, and a costly disease to manage in low/middle-income countries, which is burdensome for the most vulnerable populations, cause financial strain on individuals and family members. The purpose of the study was to analyze the price variability of different brands of sodium glucose co-transporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP4i) and their combinations. The present study was an observational analytical one. The highest and lowest price of each SGLT2i and DPP4i in the same strength marketed by different pharmaceutical companies, were collected from Current Index of Medical Specialties (Jan–April 2023), Indian Drug Review (IDR 2023), Drug Today (April – July 2023) drug manuals. Calculations were done in Indian Rupees per 10 tablets/capsules. For each drug, the cost ratio and percentage of price variation (PPV) were calculated. Among DPP4i, sitagliptin 50 mg has a maximum cost ratio (5.30) and PPV (1083.66%), while sexagliptin 2.5 mg has minimal cost ratio (1.55) and PPV (55.08%). Among SGLT2i, dapagliflozin 5 mg had the highest cost ratio (10.79) and PPV (978.79%) and remogliflozin100 mg had the lowest cost ratio (1.57) and PPV (56.94%) and among combinations dapagliflozin 10 mg+ metformin 500 mg has the highest cost ratio (6.66) and PPV (565.75%), while empagliflozin 12.5 mg + metformin 500 mg has the lowest cost ratio (1.04) and PPV (4.00%). Current study shows large differences in cost ratio as well as PPV between brands. To reduce the financial burden and treatment adherence, physicians must prescribe less expensive drugs.

Keywords: Cost analysis, Cost ratio, Percentage of price variation, Diabetes mellitus

References

  1. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. New England journal of medicine. 2017;376(15):1407–1418. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1608664
  2. Arroyave F, Montano D, Lizcano F. Diabetes Mellitus is a Chronic Disease that can benefit from therapy with induced pluripotent stem cells. International Journal of Molecular Sciences. 2020;21(22):1–28. Available from: https://doi.org/10.3390/ijms21228685
  3. Torre E, Bruno GM, Matteo SD, Martinotti C, Valentino MC, Bottaro LC, et al. Cost-utility analysis of Saxagliptin/Dapagliflozin versus Gliclazide and insulin glargine: economic implications of the outcomes of the CVD-real studies I and II. Health Services Insights. 2020;13:1–12. Available from: https://doi.org/10.1177/1178632920929982
  4. Garcia UG, Benito-Vicente A, Jebari S, Sebal AL, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. International journal of Molecular Sciences. 2020;21(17):1–34. Available from: https://doi.org/10.3390%2Fijms21176275
  5. IDF Diabetes Atlas, 10th Edition . International Diabetes Federation. Available from: http://www.diabetesatlas.org/
  8. Moucheraud C, Lenz C, Latkovic M, Wirtz VJ. The costs of diabetes treatment in low-and middle-income countries: a systematic review. BMJ Global Health. 2019;4(1):1–12. Available from: https://doi.org/10.1136/bmjgh-2018-001258
  9. Mahgoub MO, Ali II, Adeghate JO, Tekes K, Kalász H, Adeghate EA. An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus. International Journal of Molecular Sciences. 2023;24(11):1–26. Available from: https://doi.org/10.3390/ijms24119328
  10. Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. Pharmacy and Therapeutics. 2010;35(9):509–513. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957740/
  11. Dicker D. DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors. Diabetes care. 2011;34(Supplement_2)):S276–S278. Available from: https://doi.org/10.2337/dc11-s229
  12. Lim SW, Jin JZ, Jin L, Jin J, Li C. Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation. Korean Journal of Internal Medicine. 2015;30(6):759–770. Available from: https://doi.org/10.3904%2Fkjim.2015.30.6.759
  13. Baigent C, Emberson J, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet. 2022;400(10365):1788–1801. Available from: https://doi.org/10.1016/S0140-6736(22)02074-8
  14. Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Current Opinion in Nephrology and Hypertension. 2020;29(2):190–198. Available from: https://doi.org/10.1097/mnh.0000000000000584
  15. Chadha M, Das AK, Deb P, Gangopadhyay KK, Joshi S, Kesavadev J, et al. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i+ DPP4i in the Indian Diabetes Setting. Diabetes Therapy. 2022;13(5):1097–1114. Available from: https://doi.org/10.1007/s13300-022-01219-x
  16. Tandon T, Dubey AK, Srivastava S, Manocha S, Arora E, Hasan N. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. Journal of Family Medicine and Primary Care. 2019;8(3):955–959. Available from: https://doi.org/10.4103/jfmpc.jfmpc_22_19
  17. Huang K, Wang Y, Sun S, Zhu Q, Zhou W, Liu J, et al. Cost-effectiveness analysis of dapagliflozin plus standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in China. Frontiers in Public Health. 2022;10:1–12. Available from: https://doi.org/10.3389%2Ffpubh.2022.936703
  20. Pawaskar M, Bilir SP, Kowal S, Gonzalez C, Rajpathak S, Davies G. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes. The American Journal of Managed Care. 2019;25(5):231–238. Available from: https://pubmed.ncbi.nlm.nih.gov/31120717/
  21. Shyam S, Mahanthegowda BD. A cost variation analysis of various brands of oral anti-diabetic drugs currently available in Indian pharmaceutical market. International Journal of Basic & Clinical Pharmacology. 2020;9(8):1253–1257. Available from: https://doi.org/10.18203/2319-2003.ijbcp20203144
  23. Amaravati RVC, Kandra NV. Cost analysis of oral hypoglycemic agents available in Indian pharmaceutical market. National Journal of Physiology, Pharmacy and Pharmacology. 2023;13(7):1439–1443. Available from: https://dx.doi.org/10.5455/njppp.2023.13.12584202220122022
  24. Mehani R, Sharma P. Cost variation analysis of oral anti-diabetic drugs. International Journal of Basic & Clinical Pharmacology. 2018;7(9):1709–1714. Available from: https://dx.doi.org/10.18203/2319-2003.ijbcp20183476
  25. Singla R, Bindra J, Singla A, Gupta Y, Kalra S. Drug prescription patterns and cost analysis of diabetes therapy in India: Audit of an endocrine practice. Indian Journal of Endocrinology and Metabolism. 2019;23(1):40–45. Available from: https://dx.doi.org/10.4103/ijem.ijem_646_18
  26. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020;395(10225):709–733. Available from: https://dx.doi.org/10.1016/s0140-6736(20)30045-3
  27. Liu AYL, Low S, Yeoh E, Lim EK, Renaud CJ, Teoh STY, et al. A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. Clinical Kidney Journal. 2022;15(7):1403–1414. Available from: https://dx.doi.org/10.1093/ckj/sfac044
  28. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117–2128. Available from: https://dx.doi.org/10.1056/nejmoa1504720
  30. Neal B, Perkovic V, Mahaffey KW, Zeeuw Dd, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017;377(7):644–657. Available from: https://dx.doi.org/10.1056/nejmoa1611925
  31. Atal S, Fatima Z, Singh S, Balakrishnan S, Joshi R. Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus. Diabetology International. 2021;12(3):247–253. Available from: https://dx.doi.org/10.1007/s13340-020-00472-4
  32. Avogaro A, Fadini GP. The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications. Diabetes Care. 2014;37(10):2884–2894. Available from: https://dx.doi.org/10.2337/dc14-0865
  33. Vijayakumar TM, Jayram J, Cheekireddy VM, Himaja D, Teja YD, Narayanasamy D. Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review. Current Therapeutic Research. 2017;84:4–9. Available from: https://doi.org/10.1016/j.curtheres.2017.01.005
  34. Farag SS, Zaid MA, Schwartz JE, Thakrar TC, Blakley AJ, Abonour R, et al. Dipeptidyl peptidase 4 inhibition for prophylaxis of acute graft-versus-host disease. The New England Journal of Medicine. 2021;384(1):11–19. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2027372
  35. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine. 2013;369(14):1317–1326. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1307684
  36. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. The Journal of the American Medical Association. 2019;321(1):69–79. Available from: https://jamanetwork.com/journals/jama/fullarticle/2714646
  37. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine. 2015;373(3):232–242. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1501352
  39. Ceriello A, Lucisano G, Prattichizzo F, Grotta RL, Frigé C, Cosmo SD. The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. The Lancet Regional Health - Europe. 2023;31(100666):1–9. Available from: https://doi.org/10.1016/j.lanepe.2023.100666
  40. Arora S, Chatterjee AK, Banerjee M, Singh AK, Deshpande S, Tandon AK, et al. Prescription Pattern of Empagliflozin and Linagliptin Combination among Indian Health Care Practitioners. International Journal of Science and Research. 2022;11(1):659–669. Available from: https://www.ijsr.net/getabstract.php?paperid=SR22106110902

Copyright

© 2024 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 06 August 2024

Year: 2024, Volume: 23, Issue: 2


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.